NextGen Biomed 2026

15:05

Panel Discussion: NextGen Vaccine Strategies To Advance Cancer Treatment
Moderator: ANTONIO POSTIGO, Chief Scientific Officer, Stratosvir Ltd

Panel Discussion: The Next Chapter Of Oligonucleotide Delivery
Moderator: STEVE HOOD, Senior Director, Oligonucleotide ADME Strategy, DMPK, GSK

Empowering Antibody Engineering – Highlights From Early Beginnings Of Using AI-Based Tools For Optimization & Functional Engineering Of Antibody Candidates
BERIT OLSEN KROGH, Senior Research Fellow, Lundbeck

Panel Discussion: Mixed Modalities: Addressing The Challenges & Opportunities To Drug The Undruggable

Multivalent Ligand Design To Selectively Bind Proteins
NATHAN ALVES, Research Director, Indiana University School Of Medicine

15:30

Cyclotides As Ultra-Stable Combinatorial Display Platforms For Peptide-Based Drug Discovery
DAVID CRAIK, Professor, University Of Queensland

Enhancing Biologics Lead Optimisation By Combining Affinity Prediction Methods & Active Learning
OWEN VICKERY, Associate Principal Scientist, AstraZeneca

InSiDe Out: In Silico Developability Screening At AstraZeneca, Impact To Date & Future Direction
ISABELLE SERMADIRAS, Associate Principal Scientist, AstraZeneca

15:55

Unveiling Hidden Targets: AI-Driven Discovery Of Therapeutic Cancer Antigens From The Dark Genome
CHRISTIAN GARDE, Director, Evaxion

The Identification Of Cyclic Peptide Metabolic Soft Spots By Isotope-Labelled Reductive Dimethylation & Leveraging High-Resolution Ion Mobility-Mass Spectrometry
MARIA FAWAZ, Associate Principal Scientist, MS

Using The Very Small To Tackle The Very Large – Our Journey From Concept To Clinic
IJEOMA UCHEGBU, Professor Of Pharmaceutical Nanoscience, University College London

First-In-Class Site-Directed Targeted soloMER Drug Conjugate For Autoimmune Inflammation
OBINNA UBAH, Principal Scientist, Elasmogen

Rationalising MABs Developability Testing
DAVID BROCKWELL, Professor, University Of Leeds

16:20

Development & Qualification Of A Cell-Based Potency Assay For Two Novel DNA Cancer Vaccine
ELISA MARELLI, Research Scientist, Scancell

Short Novel Peptides As Chelating Agents For Metal-Related Diseases
MICHAL SHOSHAN, Founder & Chief Executive Officer, metaLead Therapeutic

Purification Of Oligonucleotides & Their Conjugates For Progressing Early Drug Discovery Projects & The Chromatographic Challenges With Oligonucleotide G-rich Sequences
YIPING WU, Senior Scientist, AstraZeneca

Removing Biological Roadblocks To Better Treatments: The Power Of Nanofitin-Enhanced Biologics
MATHIEU CINIER, Scientific Director, Affilogi

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow, Lundbeck; Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Presentation: What Does The Future Hold For Orally Available Peptides?

Presented by: Immanuel Lerner, Chief Executive Officer,
Pepticom

Oligonucleotides
Panel Discussion: The Next Chapter Of Oligonucleotide Delivery

Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK
Panellists include

Saul Martinez Montero, Senior Director, RNA Therapeutics, Dyne Therapeutics
Morten Lindow, RNAHub Founder & Mission Lead, Roche
Sritama Bose, Head Of Chemistry Research & Innovation, NATA
Fazel Shabanpoor, Co-Founder & Chief Scientific Officer & Associate Professor & Head Of Pep & Oligo Therapeutics Lab, Centron Bio & The Florey Institute

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How Vaccines & Immunotherapy Strategies: Converging Pathways For Preventing Or Treating Chronic Diseases

Presented by: Daniel Larocque, Innovation Lead, Innovation & Emerging Science, Sanofi

Anna Perdrix

Founder & Co-Chief Executive Officer,

Sixfold Bioscience

Fernando Albericio

Professor,

University of KwaZulu-Natal

Kelly Loyet

Distinguished Scientist,

Genentech

Kevin Fitzgerald

Chief Scientific Officer,

Epsilogen

Livija Deban

Chief Scientific Officer,

Prokarium

Maria Koufali

Director,

UK Vaccine Innovation Pathway

Marta Amaral

Head High Throughput Protein Engineering in Large Molecules Research,

Sanofi

Nazneen Dewji

Chief Executive Officer,

Cenna Biosciences

Philip Beer

Chief Medical Officer,

Step Pharma

Rick Hibbert

Vice President & Head of CMC Science & Technologies,

Genmab

Sudhir Agrawal

President & Founder & Affiliate Professor,

ARNAY Sciences & UMass Chan Medical School

Tristan Vaughan

Vice President Protein Engineering,

Immunocore

Aaron John Balana

Scientist III,

Genentech

Aikaterini Gatsiou

Assistant Professor,

Lancaster University

Alain Wagner

Research Director,

Strasbourg University

Alastair Lawson

Vice President,

UCB

Alessandra Tolomelli

Associate Professor,

University of Bologna

Alessandro Gori

Group Leader,

National Research Council of Italy

Alexandria Cogdill

Head of Strategic Initiatives, Global Business Development,

Daiichi Sankyo, Inc

Álvaro Enríquez García

Medicinal Chemist,

Eli Lilly

Amita Vaidya

Principal Scientist,

Sanofi

Ammar Ahmed

Senior Scientist,

Imperial College London

Amy Li

Director, Drug Discovery,

T-Therapeutics Ltd

Anand Kumar

Senior Scientist,

Sanofi

Andreas Reichel

Vice President, Head of Research Pharmacokinetics,

Bayer

Andreas Midbøe Hoff

Head of In Silico & AI Department,

Nykode

Andrew Slee

Chief Operating Officer,

AgenusBio

Andrew Jamieson

Professor Of Chemical Biology,

University of Glasgow

Andrew Buchanan

Principal Scientist: Biologics Engineering,

AstraZeneca

Andrew Creese

Associate Director,

Immunocore

Andri Vasou

Head of Platform Development,

Bioarchitech

Aneesh Karatt-Vellatt

Co.Founder & Chief Scientific Officer,

Maxion Therapeutics

Anna Hine

Professor of Protein Engineering,

Aston University

Anna Maria Papini

Full Professor and Group Leader of PeptLab,

University of Florence

Annelise Vuidepot

Chief Technology Officer,

Immunocore

Antonio Postigo

Chief Scientific Officer,

Stratosvir

Aswin Doekhie

Chief Technology Officer,

EnsiliTech

Baldur Sveinbjørnsson

Chief Scientific Officer,

Lytix Biopharma

Bassam Hallis

Deputy Director of Research and Evaluation,

UK Health Security Agency

Benjamin Lindner

Data Scientist,

Boehringer Ingelheim RCV GmbH & Co KG

Berit Olsen Krogh

Senior Research Fellow,

Lundbeck

Bernard Maillere

Head of Laboratory,

CEA

Bjorn Onfelt

Professor of Applied Physics,

Royal Institute of Technology

Brian Schanen

Global Head,

Sanofi

Caleb McClain

Chief Executive Officer,

ANUNA (AI+BIO)

Callum Scott

Head of Development,

Scancell

Carla Vinals

Vice President, Global Regulatory Product Strategy,

Moderna Therapeutics

Carol Sze Ki Leung

Principal Investigator,

Ludwig Institute, Oxford University

Charlotte Vernhes

Scientific and Medical Affairs Director,

Vaccines Europe

Christian Garde

Director,

Evaxion Biotech

Christopher Scott

Professor,

Queen's University Belfast

Dan Hardy

Chief Executive Officer,

Microsol Science

Daniel Larocque

Innovation Lead, Innovation and Emerging Science,

Sanofi Vaccines

Daniel Fonseca

Senior Research Scientist I ‑ Experimental Immunology,

Immunocore

Daniel Sejer Pedersen

Chemical Development Specialist,

Novo Nordisk A/S

David Craik

Professor,

The University of Queensland

David Brockwell

Professor,

University of Leeds

David Pejoski

Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,

Adoram Therapeutics

David Wraith

Emeritus Professor of Immunology, Institute of Immunology and Immunotherapy,

University of Birmingham

Denise Steckel

Head of Clinical Collaborations Development,

Genentech

Deniz Eris

Principal Scientist,

Novartis

Dorothy Bray

Senior Executive,

Celtic Biotech

Ed Tate

Professor,

Imperial College London

Eef Dirksen

Director Analytical Development & Quality Control,

Byondis B.V.

Elisa Marelli

Research Scientist,

Scancell

Elizabeth Boulter

Senior Scientist,

AstraZeneca

Erik Vernet

Vice President - Scientific Data Registration,

Novo Nordisk

Ernst Weber

Senior Principal Scientist and Bayer Science Fellow,

Bayer AG

Etienne Matous

Head of Lead Optimisation,

Iginnovate

Fazel Shabanpoor

Lab Head Peptide And Oligonucleotide Therapeutics,

The Florey Institute of Neuroscience and Mental Health

Felix Schumacher

Program Leader Targeted Therapeutics,

Roche

Francisca Wollerton

Senior Director,

AstraZeneca

Gabriel Wong

Senior Director Physician, Clinical Research, Immunology,

AstraZeneca

Georgios Skretas

Director,

Biomedical Sciences Research Center "Alexander Fleming"

Giulio Russo

Senior Scientist,

Merus

Hans Melo

Chief Executive Officer,

Menten Biotechnology Labs

Hans Van Der Vliet

Chief Scientific Officer,

LAVA Therapeutics

Helen Bright

Chief Scientific Officer,

Centauri Therapeutics

Helene Kaplon

Translational Scientist,

Servier

Henry Maun

Staff Scientist,

Genentech

Hester Van Zeeburg

Project Manager Immune & Disease Monitoring,

Mendus AB

Ian Hamley

Professor of Physical Chemistry,

University of Reading

Ijeoma Uchegbu

Professor of Pharmaceutical Nanoscience,

University College London

Immanuel Lerner

Chief Executive Officer,

Pepticom

Isabelle Sermadiras

Associate Principal Scientist,

AstraZeneca

Itishri Sahu

Program Lead Therapeutics,

Ziphius Vaccines

Iulia Oita

CMC Manager,

Ziphius Vaccines

Janos Tibor Kodra

Principal Scientist,

Novo Nordisk

Jean Ge

Patent Attorney,

Wolf Greenfield

Jennifer Percival-Alwyn

Scientific Leader,

GSK

John Maher

Chief Scientific Officer,

Leucid Bio

Jonathan Kwok

Chief Executive Officer,

Infinitopes

Joost Uitdehaag

Head of Biology,

Crossfire Oncology

Jörg Wischhusen

Professor,

University Hospital Würzburg

Jutta Eichler

Professor Medicinal Chemistry,

University of Erlangen-Nurnberg

Karen Silence

Head Preclinical Product Development,

Argenx BVBA

Kate Smith

Senior Director, Head of UK Protein and Cell Sciences,

GSK

Ken Chow

Health Tech Counsel,

Flanders Investment & Trade

Kerry Chester

Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,

The Antibody Society

Kevin Maskell

Research Director,

Bioarchitech

Knud Jørgen Jensen

Professor,

Copenhagen University

Kuda Muchandibaya

Lecturer for Supply Chain Management & Logistics,

Rhine-Waal University of Applied Sciences

Laura Starkie

Director,

UCB

Laura Collins

Director Bioinformatics,

Immunocore

Leonardo De Maria

Principal Scientist,

AstraZeneca

Louis Diorazio

Senior Principal Scientist,

AstraZeneca

Lucia Ferrazzano

Junior Assistant Professor,

University of Bologna

Lukas Pekar

Lab Head,

Merck

Mads Hald Andersen

Professor,

National Centre For Cancer Immune Therapy (CCIT-dk)

Mani Mudaliar

Director, Quantitative Biomarkers,

Recursion

Marc Vendrell

Professor of Translational Chemistry,

University of Edinburgh

Maria Fawaz

Associate Principal Scientist,

MSD

Marie McAvoy

Chief Scientific Officer,

Nanosyrinx

Marina Fedorova

Scientific Investigator,

GSK

Mark Eccleston

Chief Executive Officer,

ValiRx Plc.

Markus Templin

Head Of Cellular & Molecular Biology,

NMI

Martina Ochs

Project Leader,

CEPI

Mathieu Cinier

Scientific Director,

Affilogic

Matthew Burrell

Associate Director,

AstraZeneca

Mattias Malm

Senior Scientist,

Ferring Pharmaceuticals

Micaela Graglia

Analytical Chemist, Molecular Design,

Silence Therapeutics

Michael Delaney

Principal Scientist,

Novo Nordisk

Mihaela Bozic

Scientist,

T-Therapeutics

Mikhail Kuravskiy

Principal Scientist,

UCB

Nathan Alves

Research Director,

Indiana University School of Medicine

Nesrine Chakroun

Associate Director,

Merus NV

Nicola Ferrari

Director,

AstraZeneca

Norbert Furtmann

Head of AI Innovation NANOBODY® Platform,

Sanofi

Obinna Ubah

Principal Scientist,

Elasmogen Limited

Owen Vickery

Associate Principal Scientist,

AstraZeneca

Patricia Alves

Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,

Instituto de Biologia Experimental e Tecnológica

Paul Wassmann

Senior Principal Scientist,

Novartis AG

Pawel Stocki

Vice President,

Ossianix

Peter Sondermann

Chief Executive Officer,

Tacalyx GmbH Privacy Policy Imprint

Prasun Chakraborty

Chief Executive Officer and Founder,

Genevation LTD

Raj Mehta

Chief Executive Officer,

Adendra Therapeutics

Raymond Tesi

President & Chief Executive Officer,

InMune Bio

Reeta Daswani

Senior Scientist,

Sixfold

Rita Martello

Scientific Director, NBE DMPK Lead,

Merck KGaA

Robert Andrews

Biotech IP Strategist,

Mewburn Ellis LLP

Rodrigo Abreu

Principal Scientist,

LifeArc

Russell LaMontagne

Chief Executive Officer,

Boston Immune Technologies & Therapeutics (BITT)

Sagar Kathuria

Sr. Scientist, Protein Engineering I,

Sanofi

Sandor Batkai

Freelance Consultant,

Batkai.Condulting (ex-Cardior Pharmaceuticals)

Sandra Tremmel

Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,

Roche

Sandrien Janssens

CMC Director,

Mosanna Therapeutics

Santiago Parpal

Principal Scientist,

Sprint Bioscience

Sarah Stuart

High Throughput Characterisation Team Leader,

GSK

Sarah Hindson

Senior Scientist,

GSK

Saurabh Sen

Associate Director, Cell Line Development, Mammalian Platform Biologics,

Sanofi

Sebastian Sten

Associate Principal Scientist,

AstraZeneca

Sevim Ozgur Bruderle

Lab Head,

Sanofi

Shao-An Xue

Senior Scientist,

University College London

Silvia Crescioli

Business Intelligence Creator,

The Antibody Society

Simon Hufton

Section Head Molecular Immunology, Division of Biotherapeutics,

MHRA

Simone Friedrich

Director Antibody Discovery & Development,

iOmx Therapeutics

Sonia Macia

Chief Medical Officer,

Aromics Therapeutics

Sonja Merkas

Founder,

Livinovea GmbH

Sophia Karagiannis

Professor of Translational Cancer Immunology and Immunotherapy,

King's College London

Sritama Bose

Head of Chemistry Research and Innovation,

NATA

Stefan Zielonka

Senior Director,

Merck KGaA

Stephen Miller

Principal Scientist,

Genentech

Steve Hood

Senior Director, Oligonucleotide ADME Strategy, DMPK,

GSK

Steven Schmitt

Co-Founder & Chief Executive Officer,

Myria Biosciences

Stine Friis Thorsen

Director Clinical Development,

Evaxion Biotech

Sue Charlton

Head of Clinical Evaluation,

UKHSA

Talip Ucar

Senior Director,

AstraZeneca

Tatyana Ponomaryov

Principal Scientist,

Plasticell Limited

Thomas Kraft

Principal Scientist,

Roche

Thomas Powell

Senior Scientist,

Immunocore

Timothy Hickling

Immunogenicity Expert Scientist,

Roche

Tomasz Witkos

Associate Director,

AstraZeneca

Toria Legh-Land

Computational Pharmaceutics Lead,

Microsol

Trevor Smith

Vice President,

Inovio

Ulrike Rieder

Scientific Lead,

Novartis

Vaios Karanikas

Biomarker Experimental Medicine Leader, Oncology,

Hoffmann La Roche Ltd

Vik Reebye

Head of Academic Partnership,

MiNA Therapeutics Ltd

Vincent Dewar

Head of Immunoassay,

GSK

Vincenzo de Filippis

Associate Professor Biochemistry,

University of Padova

Walter Cabri

Professor,

Fresenius Kabi

Wen Chang

Associate Vice President Discovery and Early Development,

AcuraStem

Will Nesbit

Senior Director - Process Chemistry & CMC,

Bicycle Therapeutics

Wolfgang Koch

Senior Scientist,

F-star Therapeutics Inc

Yann Abraham

Associate Director AI for Single Cell,

Johnson & Johnson Innovative Medicine

Yiping Wu

Senior Scientist,

AstraZeneca

Zahra Rattray

Senior Lecturer,

University of Strathclyde

Zinaida Dedeic

Senior Scientist,

University of Oxford

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

Advanced Therapies Specialist Team Leader,
Genscript

Biologics 2024 has been one of the best events I have attended so far in my career.

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Impressed by the effort to bring people together.

Business Development Director,

Bioassay

Nice set-up, with good support for exhibitors

Director of Client Relations,

ImmunoPrecise

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

In-Person Services Digital Marketing Services